These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 16778979)

  • 21. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation.
    Fu Y; Wang L; Xie C; Zou K; Tu L; Yan W; Hou X
    Sci Rep; 2017 Jun; 7(1):2669. PubMed ID: 28572616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
    Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
    Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal calprotectin in inflammatory bowel diseases: update and perspectives.
    Manceau H; Chicha-Cattoir V; Puy H; Peoc'h K
    Clin Chem Lab Med; 2017 Mar; 55(4):474-483. PubMed ID: 27658156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.
    Schoepfer AM; Trummler M; Seeholzer P; Seibold-Schmid B; Seibold F
    Inflamm Bowel Dis; 2008 Jan; 14(1):32-9. PubMed ID: 17924558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis.
    Önal İK; Beyazit Y; Şener B; Savuk B; Özer Etık D; Sayilir A; Öztaş E; Torun S; Özderın Özın Y; Tunç Demırel B; Ülker A; Dağli Ü
    Turk J Gastroenterol; 2012; 23(5):509-14. PubMed ID: 23161295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Faecal calprotectin: a new marker for Crohn's disease?
    Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
    Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Faecal calprotectin concentrations in gastrointestinal diseases.
    Wang S; Wang Z; Shi H; Heng L; Juan W; Yuan B; Wu X; Wang F
    J Int Med Res; 2013 Aug; 41(4):1357-61. PubMed ID: 23723365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Faecal calprotectin: a marker of inflammation throughout the intestinal tract.
    Summerton CB; Longlands MG; Wiener K; Shreeve DR
    Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):841-5. PubMed ID: 12172403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
    Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
    Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease.
    Tibble JA; Sigthorsson G; Foster R; Forgacs I; Bjarnason I
    Gastroenterology; 2002 Aug; 123(2):450-60. PubMed ID: 12145798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go?
    Nemakayala DR; Cash BD
    Curr Opin Gastroenterol; 2019 Jan; 35(1):58-62. PubMed ID: 30407259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy.
    Limburg PJ; Ahlquist DA; Sandborn WJ; Mahoney DW; Devens ME; Harrington JJ; Zinsmeister AR
    Am J Gastroenterol; 2000 Oct; 95(10):2831-7. PubMed ID: 11051356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of faecal calprotectin as non-invasive marker of intestinal inflammation.
    Costa F; Mumolo MG; Bellini M; Romano MR; Ceccarelli L; Arpe P; Sterpi C; Marchi S; Maltinti G
    Dig Liver Dis; 2003 Sep; 35(9):642-7. PubMed ID: 14563186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome.
    Campbell JP; Zierold C; Rode AM; Blocki FA; Vaughn BP
    J Clin Gastroenterol; 2021 Mar; 55(3):239-243. PubMed ID: 32324678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
    Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
    World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis.
    Annaházi A; Molnár T; Farkas K; Rosztóczy A; Izbéki F; Gecse K; Inczefi O; Nagy F; Földesi I; Szűcs M; Dabek M; Ferrier L; Theodorou V; Bueno L; Wittmann T; Róka R
    Inflamm Bowel Dis; 2013 Feb; 19(2):316-20. PubMed ID: 22550024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
    Konikoff MR; Denson LA
    Inflamm Bowel Dis; 2006 Jun; 12(6):524-34. PubMed ID: 16775498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome.
    Langhorst J; Junge A; Rueffer A; Wehkamp J; Foell D; Michalsen A; Musial F; Dobos GJ
    Am J Gastroenterol; 2009 Feb; 104(2):404-10. PubMed ID: 19174795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.